Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726978 | 0.94 | TYK2 (0.38) | HTR3APOLBLMNAIRAK4TYK2 | |
| SCHEMBL21246081 | 0.94 | TYK2 (0.38) | HTR3APOLBLMNAIRAK4TYK2 | |
| SCHEMBL21227353 | 0.92 | POLB (0.40) | POLBLMNAIRAK4KDM4EALDH1A1 | |
| SCHEMBL20689036 | 0.84 | ALDH1A1 (0.39) | POLBKDM4EALDH1A1TYK2 | |
| SCHEMBL20696960 | 0.83 | TYK2 (0.38) | TYK2 | |
| SCHEMBL21238770 | 0.81 | KMT2A (0.35) | IRAK4KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL20689242 | 0.79 | TYK2 (0.45) | POLBKDM4EALDH1A1TYK2 | |
| SCHEMBL21238833 | 0.79 | TYK2 (0.45) | POLBKDM4EALDH1A1TYK2 | |
| SCHEMBL20688110 | 0.79 | TYK2 (0.45) | POLBKDM4EALDH1A1TYK2 | |
| SCHEMBL20689599 | 0.79 | TYK2 (0.45) | POLBKDM4EALDH1A1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HTR3A 3557/4885POLB 1657/4885LMNA 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.